Promising Pre-clinical Validation of Targeted Radionuclide Therapy Using a $[^{131}I]$ Labelled Iodoquinoxaline Derivative for an Effective Melanoma Treatment

Bonnet-Duquennoy M$^{1,4}$, Papon J$^1$, Mishellany F$^2$, Denoyer D$^1$, Labarre P$^2$, Guerquin-Kern JL$^{1,4}$, Penault-llorca F$^3$, Madelmont JC$^1$, Miot-Noirault E$^1$, Cayre A$^2$, Chezal JM$^1$, Moins N$^1$

$^1$Clermont Université/ Univ Clermont 1, EA 4231/ Clermont-Ferrand, BP 184, F-63001 France
$^2$Centre Jean Perrin, Laboratoire d’anatomo-pathologie, Clermont-Ferrand, F-63011, France
$^3$Institut Curie, Laboratoire de Microscopie Ionique, 91405 Orsay, France
$^4$Inserm, U759, 91405 Orsay, France

Abstract

Targeted internal radionuclide therapy (TRT) would be an effective alternative to current therapies for disseminated melanoma treatment. At our institution, a class of iodo benzamides has been developed as potent melanoma-seeking agents. This review described the preclinical validations of a quinoxaline derivative molecule (ICF01012) as tracer for TRT application. It was selected for its high, specific and long-lasting uptake in tumour with rapid clearance from non-target organs providing suitable dosimetry parameters for TRT. Extended in vivo study of metabolic profiles confirmed durable tumoural concentration of the unchanged molecule form. Moreover melanin specificity of ICF01012 was determined by binding assay with synthetic melanin and in vivo by SIMS imaging. Then, we showed in vivo that $[^{131}I]$ ICF01012 treatment drastically inhibited growth of B16F0, B16B16 and M4Beu tumours whereas $[^{131}I]$ NaI or unlabelled ICF01012 treatment was without significant effect. Histological analysis showed that residual tumour cells exhibit a significant loss of aggressiveness after treatment. This anti-tumoural effect was associated with a lengthening of the treated-mice survival time and an inhibition of lung dissemination for B16B16 model.

Results presented here support the concept of TRT using a $[^{131}I]$ labelled iodoquinoxaline derivative for an effective melanoma treatment.

Introduction

Melanoma is a poor prognosis skin cancer that affects about 150000 new patients per year in world. Despite recent advances in prevention and early diagnosis, malignant melanoma remains an increasingly prevalent cancer worldwide (Lorigan et al., 2008; Thompson et al., 2005). It is notably the second most common cancer among patients aged 20–39 years (Garbe and Leiter, 2009; Jennings and Murphy, 2009; Thompson et al., 2005). This aggressive disease displays a strong tendency to metastasize. Although localized disease is frequently curable by surgical removal, there is no effective treatment for metastatic melanoma. Patients with metastatic malignant melanoma have an average median survival rate of 6 months and a 5-year survival rate of less than 15% (Balch et al., 2001; Miller and Mihm, 2006). There are several approved therapies for malignant melanoma treatment as dacarbazine (an alkylating agent) and interleukin-2. However, the response rate obtained with these therapies remains low (less than 20%) and contributes little to overall patient survival (Tarhini and Agarwala, 2006). A higher response rate of up to 40% may be obtained with combined treatment schedules, but without significant prolonged survival in randomized studies (Hauschild et al., 2001; Tarhini and Agarwala, 2006). Globally, the response rate is still rather low and there has been no progress in systemic palliative melanoma treatment for three decades partly due to their high toxicity (Eigentler et al., 2003; Garbe and Eigentler, 2007). In this context, there is an urgency to develop more effective therapy and to find new more specific ways to treat disseminated melanoma.

Identification of signalling pathways that are central to melanoma initiation and progression, provides opportunity to develop targeted therapies. Several clinical investigations are under way in patients with melanoma testing these novel agents (Bcl-2 antisense, BRAF inhibitors as BAY 43-906, heat shock protein 90 inhibitor, angiogenesis inhibitor, melanoma vaccine strategies…) (Carlson et al., 2007; Gray-Schopfer et al., 2007). At this time, it seems difficult to transpose the encouraging results obtained in preclinical studies and no real benefit in term of global survival has been demonstrated with these agents (Bedikian et al., 2006; Fecher et al., 2008; Gray-Schopfer et al., 2007). Involvement of these different targeted pathways in the melanoma development as well as their interactions must be better understood to exploit these new strategies.

Targeted radionuclide therapy (TRT) is a potentially important alternative to conventional therapeutic agents. In comparison with standard therapies (external beam...
radiotherapy or monochemotherapy), TRT offers the potential of tumour-selective radio-therapeutic treatment of tumours and distal metastases. This approach is under development for several tumoral pathologies with success. First radio-immunotherapy with name Zevalin® was approved by FDA in 2002 for treatment of non-Hodgkin’s lymphoma (Conti et al., 2005; Wiseman et al., 2000).

Different carriers for radionuclides and melanoma targets are being investigated. Peptide analogues of α-melanocyte stimulating hormone (α-MSH) targeting melanocortin-1 receptor have been developed and provide good quality imaging in melanoma-bearing mice (Miao et al., 2008; Miao and Quinn, 2007; Ren et al., 2009). For a systemic radionuclide therapy, promising experimental results in melanoma-bearing mice have been reported (Miao et al., 2005; Miao and Quinn, 2008). However, high kidney concentration may results in a restricting renal toxicity.

Melanin pigment itself can be a target for melanoma tissue. Melanin is an amorphous, irregular polymer composed of intimate mixtures of two separated but biogenetically related pigments: eumelans and pheomelans (Prota, 2000). Recently, radioimmunotherapy using mAb against melanin has been developed and evaluated on nude mice bearing human melanoma. Significant anti-tumoural effect has been obtained but important renal uptake is also detected with this treatment (Dadachova et al., 2004; Dadachova et al., 2008).

Many drugs bind to melanin both in vivo and in vitro: polycyclic aromatic compounds such methylene blue (MTB), chloroquine or acridine orange. An extended experimental work has been done with ¹³¹I or ²¹¹At labelled MTB giving some promising data but without further clinical development (Link, 1999).

Another class of aromatic compounds with a cationic site such as N-(2-diethylaminoethyl) iodobenzamide was developed as potent melanoma-seeking agents. Two of these compounds named respectively BZA and BZA₂, have been clinically evaluated as suitable imaging agents in nuclear medicine with very encouraging results for metastases imaging (Michelot et al., 1993; Moins et al., 2002). The BZA intracellular localization within melanin-containing structures has been clearly visualized with analytical imaging by secondary ion mass spectrometry (Guerquin-Kern et al., 2005). Various iiodinated benzamides have been evaluated showing in vivo distribution profiles with a high and specific tumour uptake that was promising for imaging (Eisenhut et al., 2000; Moins et al., 2001; Pham et al., 2007). However biodistribution profiles of these tracers were not compatible for radiotherapy strategy in term of potential delivered dose to the tumour.

**Selection of ICF01012 tracer for targeted radionuclide therapy of melanoma**

**Pharmacomodulation study:** To discover new molecular derivatives for targeted radionuclide therapy with strong,

---

**Figure 1:** (A) Chemical structure of BZA₂ and ICF01012. (B) Representative scintigraphic planar images of a B16F0-bearing C57Bl6 mouse. Mice were injected intravenously with 3.7 MBq [¹²⁵I] ICF01012. Images were acquired at 1, 6, 24, 72 hours and 8 days after injection. Tumours were easily visualized (T) suggesting a significant [¹²⁵I] ICF01012 tumoural concentration. Moreover rapid systemic elimination was quite complete from non target organs 24 hours p.i. (Miot-Noirault et al., 2009) (C) Representative whole-body autoradiography of a mouse bearing B16F0 melanoma cell xenograft, 72 h after i.v. injection of 1.7 MBq (0.1 µmol) [¹²⁵I] ICF01012. T: Tumour; E: eyes. (D) Tumoural distribution radioactivity in nude mice bearing B16F0 melanoma cell xenograft after i.v. injection of [¹²⁵I] ICF01012 and [¹²⁵I] BZA₂.
specific and long-lasting uptake in melanoma tissues, a large pharmacomodulation study was performed (Chezal et al., 2008). This strategy involved the incorporation of aromatic or heteroaromatic structures in place of the phenyl moiety of BZA, to take advantage of polycyclic aromatic compounds that display a strong affinity for melanin, while the lipophilic side chain was kept identical. Then, various iodo (hetero) aromatic fused ring systems with a carboxamide part were synthesized and radioiodinated. Biodistribution of these compounds radiolabelled with $^{125}$I was performed in B16F0 melanoma bearing C57Bl6 mice after i.v. injection. The radioactivity biodistribution was analysed by quantitative whole body autoradiography using an AMBIS 4000 detector on whole body slices of mice obtained by cryosection. The radioactivity was quantified in different organs including tumour and expressed as a percentage of injected dose/g of tissue (%ID/g). Dosimetry parameters for a $^{131}$I utilization were extrapolated using an adaptation of the MIRD program. From this study a quinoxaline derivative molecule (N-(2-diethylaminoethyl)-6-iodoquinoxaline-2-carboxamide dihydrochloride salt named ICF01012) was selected for its high, specific and long-lasting uptake in melanoma tissues, a large pharmacomodulation study was performed (Chezal et al., 2008). In comparison with $^{125}$I ICF01012 renal uptake is very low (undetectable 24 hours after injection) by comparison with other targeting-melanin molecules as antibodies and $\alpha$-MSH peptide analogues (Dadachova et al., 2008; Miao et al., 2005).

To trace and quantify the metabolic fate of $^{125}$I ICF01012 in B16F0 melanoma bearing mice, high-performance liquid chromatography (HPLC) analysis were performed on tumour (Denoyer et al., 2008). Many HPLC peaks were identified in tumoural extracts with the major peak corresponding to the non-metabolized form of $^{125}$I ICF01012. Eight days post-injection, 83.6% of the remaining radioactivity is under $^{125}$I ICF01012 unchanged form.

All these promising data made this tracer a strong melanoma seeking agent for both scintigraphic imaging and radionuclide therapy (Chezal et al., 2008).

**Melanin specificity:** In experiments presented above, we observed B16F0 melanoma targeting using our quinoxaline analogue tracer. We verified the melanin specificity of $^{125}$I ICF01012 using a binding assay with synthetic melanin. We showed that $^{125}$I ICF01012 displayed a strong affinity for synthetic melanin in water and in PBS (Chezal et al., 2008). Additional study was performed to visualised in vivo ICF01012 melanin specificity by Secondary ion mass spectrometry

| Hours p.i. | 1  | 3  | 6  | 24 | 72 | 120 | 192 |
|------------|----|----|----|----|----|-----|-----|
| **Tumour** | 21.9±4.725 | 27.38±6.27 | 37.24±7.12 | 20.67±6.38 | 12.45±1.61 | 5.37±3.18 | 3.77±0.43 |
| **Brain**  | 2.17±0.93 | 0.52±0.73 | 0.39±0.47 | 0.06±0.08 | ND | 9.55 | 344.5 |
| **Stomach**| 22.06±5.35 | 20.64±9.48 | 21.35±3.02 | 0.96±1.12 | 2.23±0.38 | ND | 21.5 |
| **Liver**  | 13.95±1.32 | 8.77±1.11 | 7.69±0.65 | 1.51±0.08 | ND | 4.8 | 13.7 |
| **Bone**   | 4.7±0.45 | ND | 0.34±0.69 | UD | UD | ND | 109.5 |
| **Marrow** | 2.06±0.41 | 0.88±0.17 | 0.84±0.07 | 0.00±0.05 | UD | UD | 44.3 |
| **Muscle** | 7.96±0.74 | 5.76±0.31 | 3.91±0.71 | 0.18±0.26 | UD | 9.5 | 114.8 |
| **Spleen** | 15.6±4.99 | 2.35±3.32 | 1.39±1.62 | 0.11±0.14 | UD | 26.8 | 187.9 |
| **Kidney** | 16.3±3.54 | 8.95±2.44 | 7.23±1.64 | 0.49±0.57 | UD | 5.2 | 42.2 |
| **Blood**  | 2.89±0.67 | 2.9±0.06 | 3.19±0.19 | 0.40±0.12 | UD | 11.7 | 51.7 |
| **Uvea**   | 30.75±4.78 | 24.79±0.08 | 30.52±5.27 | 30.06±5.58 | 25.26±8.38 | 17.21±6.67 | 15.34±1.44 |

Table 1: Biodistribution of radioactivity (%ID/g) in C57Bl6 mice bearing B16 melanoma at various time after i.v. injection of $^{125}$I ICF01012. Melanoma/ Organ Ratios of $^{125}$I ICF01012 at 6 and 24 hours p.i.

ISSN:1948-5956 JCST, an open access journal
(SIMS) imaging (Bonnet-Duquennoy et al., 2009). With this technique, we observed a perfect co-localization of ICF01012 signal with melanin confirming the melanin binding properties of this tracer and its internalization in melanoma cells.

Moreover, we noted on biodistribution study (Table 1) an important radioactivity concentration on uvea confirming the high ICF01012 specificity for pigmented structures and so for melanin (Chezal et al., 2008). However fixation of tracer on normal pigmented tissues in these pre-clinical experiments should not be considered as a limit for our strategy. Indeed these experiments were performed on the heavily pigmented C57BL/6J mice associated with an important uveal melanin content which is not predictive for human status of uvea. On a clinical imaging study with $^{[125]}$I BZA, the parental benzamide analogue of ICF01012, no significant uveal uptake was imaged excepted for an ocular melanoma case while important uveal uptake was observed with the same tracer on this mouse model (Moin et al., 2002; Sillaire-Houtmann et al., 2004). Because of murine and human differences on ocular geometry and melanin content, ICF01012 accumulation within C57Bl6 mice eyes should not be considered as hampering for clinical transfer of this radiotherapy concept. Nevertheless this point has to be taking into account in our studies.

**In vivo anti-tumoural efficacy of TRT**

Several radionuclides are developed for the treatment of oncological diseases. Various approaches using $^{[131]}$I for TRT were developed to treat different cancers because of its relatively low beta energy with a maximum range of 3 mm in tissue which is effective for treatment (Kassis and Adelstein, 2005). Some of them have resulted in very good curative responses like $^{[131]}$I treatment of thyroid cancer and its micrometastases (Nijsen et al., 2007; Verburg et al., 2005). Biodistribution properties of $^{[131]}$I ICF01012 molecule provide suitable dosimetry parameters using a labelling with $^{131}$I. Indeed an administered dose of 37 MBq will allow the delivery of 49 Gy to the tumour, a usefully high dose for a good therapeutic efficacy (Chezal et al., 2008).

We investigated the *in vivo* therapeutic efficacy of $^{[131]}$I ICF01012 as a radionuclide therapeutic agent (Bonnet-Duquennoy et al., 2009) on murine melanoma models B16F0 and on the metastatic B16Bl6 cell lines grafted s.c. into syngenic C57Bl6/6J mice (Poste et al., 1980). $^{[131]}$I ICF01012 was administered i.v. at days 6 and 10 (2x18.5 MBq). Control groups received $^{[131]}$I Na or unlabelled ICF01012 (equimolar dose). All groups contained at least 10 animals and experiments were performed twice. The survival of $^{[131]}$I ICF01012-treated mice, with a median of 39 days, was significantly (p=0.006) better than that of untreated group whereas that of $^{[131]}$I NaI-treated mice was similar (p=0.3). These results suggested that $^{[131]}$I ICF01012 treatments showed low toxicity confirming precedent pharmacokinetic experiments and rapid systemic elimination.

We observed that the treatment with unlabelled ICF01012 was without any significant effect whereas $^{[131]}$I ICF01012 treatment drastically suppressed the growth of both B16F0 (p=0.001) and B16Bl6 (p=0.009) tumours. Figure 2A illustrates the strong difference on B16Bl6 tumour size at day 19 between control and treated animals. $^{[131]}$I NaI alone did not have any efficacy against tumour growth showing interest of targeting strategy with $^{[131]}$I ICF01012 for an efficient therapeutic effect (Bonnet-Duquennoy et al., 2009).

In term of proliferation, the tumour volume doubling time (DT) was determined to quantify precisely the tumoural growth. After $^{[131]}$I ICF01012 treatment, DT was significantly increased (range +44 to +147%) confirming inhibition of tumoural growth. Histological analysis showed that after targeted radiotherapy treatment, residual tumoural cells exhibited a decrease of mitotic index and microvesSEL numbers and an increase of anisocytosis. This effect was associated with a significant decrease of the tumoural PCNA proliferation marker expression after treatment. All these results suggested a loss of aggressiveness of residual tumour cells after $^{[131]}$I ICF01012 treatment (Bonnet-Duquennoy et al., 2009).

After macroscopic analysis, we observed that 55% of the untreated mice bearing B16Bl6 tumours had lung metastases whereas no metastasis was counted on $^{[131]}$I ICF01012 treated group (Figure 2B) suggesting an inhibitory effect of this treatment on lung dissemination (Bonnet-Duquennoy et al., 2009).
Results presented here support the concept of targeted radionuclide therapy using a \[^{131}I\] labelled iodoquinonaxline derivative for an effective melanoma treatment.

**Acknowledgements**

We warmly thank Pr J. Teulade and Dr O. Chavignon for their encouragement and fruitful discussions, and M Bayle for technical assistance. We acknowledge the French “Agence Nationale de la Recherche” and the “Ligue Régionale contre le Cancer” for their financial support. M. Bonnet-Duquennoy was supported by an INSERM young researcher financing.

**References**

1. Balch CM, Soong SJ, Gershenwald JE, Thompson JP, Reintgen DS, et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634. » CrossRef » PubMed » Google Scholar

2. Bediakian AY, Millward M, Pehamberger H, Conry R, Gore M, et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738-4745. » CrossRef » PubMed » Google Scholar

3. Bonnet-Duquennoy M, Papin J, Mishellany F, Labarre P, Guerquin-Kern JL, et al. (2009) Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent. Int J Cancer 125:708-716. » CrossRef » PubMed » Google Scholar

4. Carlson JA, Linette GP, Aplin A, Ng B, Slominski A (2007) Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol Clin 25: 541-557. » CrossRef » PubMed » Google Scholar

5. Chezal JM, Papin J, Labarre P, Lartigue C, Galmier MJ, et al. (2008) Evaluation of radioabeled (hetero)aromatic analogues of N-[2-diethylaminoethyl]-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem 51: 3133-3144. » CrossRef » PubMed » Google Scholar

6. Conti PS, White C, Pieslor P, Molina A, Aussie J, et al. (2005) The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med 46: 1812-1818. » CrossRef » PubMed » Google Scholar

7. Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, et al. (2004) Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci USA 101: 14865-14870. » CrossRef » PubMed » Google Scholar

8. Dadachova E, Revskaya E, Sesay MA, Damania H, Boucher R, et al. (2008) Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther 7: 1166-1172. » CrossRef » PubMed » Google Scholar

9. Denoyer D, Labarre P, Papin J, Miot-Noirault E, Galmier MJ, et al. (2009) Targeted radionuclide therapy of melanoma: high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J Med Chem 43: 3913-3922. » CrossRef » PubMed » Google Scholar

10. Eigenthaler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748-759. » CrossRef » PubMed » Google Scholar

11. Eisenbuth M, Hull WE, Mohammed A, Mier W, Lay D, et al. (2000) Radiodiomnated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J Med Chem 43: 3913-3922. » CrossRef » PubMed » Google Scholar
Citation: Bonnet-Duquennoy M, Papon J, Mishellany F, Denoyer D, Labarre P, et al. (2009) Promising Pre-clinical Validation of Targeted Radionuclide Therapy Using a [131I]-Labelled Iodoquinoxaline Derivative for an Effective Melanoma Treatment. J Cancer Sci Ther 1: 001-007. doi:10.4172/1948-5956.1000001

12. Fecher LA, Amaravadi RK, Flaherty KT (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20: 183-189. <CrossRef> <PubMed> <Google Scholar>

13. Garbe C, Eigentler TK (2007) Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17: 117-127. <CrossRef> <PubMed> <Google Scholar>

14. Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clinics in dermatology 27: 3-9. <CrossRef> <PubMed> <Google Scholar>

15. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445: 851-857. <CrossRef> <PubMed> <Google Scholar>

16. Gueguin-Kern JL, Wu TD, Quintana C, Croisy A (2005) Progress in analytical imaging of the cell by dynamic secondary ion mass spectrometry (SIMS microscopy). Biochim Biophys Acta 1724: 228-238. <CrossRef> <PubMed> <Google Scholar>

17. Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, et al. (2001) Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 84: 1036-1042. <CrossRef> <PubMed> <Google Scholar>

18. Jennings L, Murphy GM (2009) Predicting outcome in melanoma: where are we now. Br J Dermatol 161: 496-503. <CrossRef> <PubMed> <Google Scholar>

19. Kassis AI, Adelstein DJ (2005) Radiobiologic principles in radionuclide therapy. J Nucl Med 46: 12S-12S. <CrossRef> <PubMed> <Google Scholar>

20. Lazova R, Klump V, Pawelek J (2009) Autophagy in cutaneous malignant melanoma. J Cutan Pathol. 26: 28-35. <CrossRef> <PubMed> <Google Scholar>

21. Link EM (1999) Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience. Hybridoma 18: 77-82. <CrossRef> <PubMed> <Google Scholar>

22. Lorrigan P, Eisen T, Hauschild A (2008) Systemic therapy for metastatic malignant melanoma—from deeply disappointing to bright future. Exp Dermatol 17: 383-394. <CrossRef> <PubMed> <Google Scholar>

23. Miao Y, Figueroa SD, Fisher DR, Moore HA, Testa RF, et al. (2008) 203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med 49: 823-829. <CrossRef> <PubMed> <Google Scholar>

24. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, et al. (2005) Melanoma therapy via peptide-targeted (alpha)-radiation. Clin Cancer Res 11: 5616-5621. <CrossRef> <PubMed> <Google Scholar>

25. Miao Y, Quinn TP (2007) Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front Biosci 12: 4514-4524. <CrossRef> <PubMed> <Google Scholar>

26. Miao Y, Quinn TP (2008) Peptide-targeted radionuclide therapy for melanoma. Curr Rev Oncol Hematol 67: 213-228. <CrossRef> <PubMed> <Google Scholar>

27. Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, et al. (1993) Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl-4-iodobenzamide). J Nucl Med 34: 1260-1266. <CrossRef> <PubMed> <Google Scholar>

28. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355: 51-65. <CrossRef> <PubMed> <Google Scholar>

29. Miot-Noirault E, Papon J, Gardette M, Bonnet-Duquennoy M, Labarre P, et al. (2009) The use of ([125I]) scintigraphic in vivo imaging in melanoma-bearing mice for a rapid prescreening of vectors to melanoma tissue. Cancer Biother Radiopharm 24: 629-636. <CrossRef> <PubMed> <Google Scholar>

30. Moins N, D’Incan M, Bonafous J, Bacin F, Labarre P, et al. (2002) 123I-N-(2-diethylaminoethoxy)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med Mol Imaging 29: 1478-1484. <CrossRef> <PubMed> <Google Scholar>

31. Moins N, Papon J, Seguin H, Gardette D, Moreau MF, et al. (2001) Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl Med Biol 28: 799-808. <CrossRef> <PubMed> <Google Scholar>

32. Nijssen JF, Krigger GC, van Het Schip AD (2007) The bright future of radionuclides for cancer therapy. Anticancer Agents Med Chem 7: 271-290. <CrossRef> <PubMed> <Google Scholar>

33. Pham TQ, Berghofer P, Liu X, Greguric I, Dikic B, et al. (2007) Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma. J Nucl Med 48: 1348-1356. <CrossRef> <PubMed> <Google Scholar>

34. Poste G, Doll J, Hart IR, Figdler IJ (1980) In vitro selection of the melanoma cell line by dynamic secondary ion mass spectrometry (SIMS microscopy). Biochim Biophys Acta 49: 823-829. <CrossRef> <PubMed> <Google Scholar>

35. Prota G (2000) Melanins, melanogenesis and melanocytes: looking at their functional significance from the chemist’s viewpoint. Pigment Cell Res 13: 283-293. <CrossRef> <PubMed> <Google Scholar>

36. Ren G, Liu Z, Miao Z, Liu H, Subbarayan M, et al. (2009) PET of malignant melanoma using 18F-labeled metalloproteinidetides. J Nucl Med 50: 1865-1872. <CrossRef> <PubMed> <Google Scholar>

37. Revskaya E, Jongco AM, Sellers RS, Howell RC, Koba W, et al. (2009) Radiomunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Clin Cancer Res 15: 2373-2379. <CrossRef> <PubMed> <Google Scholar>

38. Sillaire-Houtmann I, Bonafoius J, Veyre A, Mestas D, D’Incan M, et al. (2004) Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma. J Fr Ophtalmol 27: 34-39. <PubMed> <Google Scholar>

39. Tarhini AA, Agarwala SS (2006) Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19: 19-25. <CrossRef> <PubMed> <Google Scholar>

40. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365: 687-701. <CrossRef> <PubMed> <Google Scholar>

41. Verburg FA, de Keizer B, Lips CJ, Zelissen PM, de Klerk JM (2005) Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 152: 33-37. <CrossRef> <PubMed> <Google Scholar>

42. Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, et al. (2000) Phase I/II 90Y-Zevalin (ytrrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 27: 766-777. <CrossRef> <PubMed> <Google Scholar>
OMICS Publishing Group

List of Journals

1. Journal of Proteomics & Bioinformatics (JPB) Open Access
2. Journal of Bioequivalence & Bioavailability (JBB) Open Access
3. Journal of Computer Science & Systems Biology (JCSB) Open Access
4. Journal of Antivirals & Antiretrovirals (JAA) Open Access
5. Journal of Data Mining in Genomics & Proteomics (JDMGP) Open Access
6. Journal of Glycomics & Lipidomics (JGL) Open Access
7. Journal of Pharmacogenomics & Pharmacoproteomics (JPP) Open Access
8. Journal of Postgenomics: Drug & Biomarker Development (JPDBD) Open Access
9. Journal of Biochips and Tissue Chips (JBTC) Open Access
10. Journal of Molecular Biomarkers & Diagnosis (JMBD) Open Access
11. Journal of Bioanalysis & Biomedicine (JBABM) Open Access
12. Journal of Nanomedicine & Biotherapeutic Discovery (JNBD) Open Access
13. Journal of Cancer Science & Therapy (JCST) Open Access
14. Journal of Biotechnology & Biomaterials (JBTBM) Open Access
15. Journal of Petroleum & Environmental Biotechnology (JPEB) Open Access
16. Journal of Microbial & Biochemical Technology (JMBT) Open Access
17. Journal of Tissue Sciences & Engineering (JTSE) Open Access
18. Briefings in Intellectual Property Rights (BIPR) Open Access